<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Palatin Technologies, Inc. — News on 6ix</title>
<link>https://6ix.com/company/palatin-technologies-inc</link>
<description>Latest news and press releases for Palatin Technologies, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Feb 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/palatin-technologies-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d77bd951cc36e475340b39.webp</url>
<title>Palatin Technologies, Inc.</title>
<link>https://6ix.com/company/palatin-technologies-inc</link>
</image>
<item>
<title>Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 17 Feb 2026 12:30:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results for its fiscal second quarter ended December 31, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-technologies-announces-closing-of-upsized-dollar182-million-public-offering-with-the-full-exercise-of-the-underwriters-over-allotment-option</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-technologies-announces-closing-of-upsized-dollar182-million-public-offering-with-the-full-exercise-of-the-underwriters-over-allotment-option</guid>
<pubDate>Wed, 12 Nov 2025 17:15:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced underwritten public offering of 2,795,384 shares of its common stock (or pre-funded warrants in lieu thereof), which included the full exercise of the underwriters' option to purchase 364,615 additional shares of common</description>
</item>
<item>
<title>Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-reports-fiscal-year-2025-third-quarter-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-reports-fiscal-year-2025-third-quarter-results-and-business-update</guid>
<pubDate>Wed, 14 May 2025 11:30:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2025.</description>
</item>
<item>
<title>Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-presents-promising-preclinical-data-on-melanocortin-agonists-for-retinopathy-at-arvo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-presents-promising-preclinical-data-on-melanocortin-agonists-for-retinopathy-at-arvo-2025</guid>
<pubDate>Fri, 09 May 2025 11:30:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new preclinical data on its melanocortin agonists PL9654 and PL9655 at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.</description>
</item>
<item>
<title>Palatin Technologies Announces Closing of Reduced Public Offering</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-technologies-announces-closing-of-reduced-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-technologies-announces-closing-of-reduced-public-offering</guid>
<pubDate>Fri, 09 May 2025 02:19:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the "Se</description>
</item>
<item>
<title>Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-presents-breakthrough-symptom-resolution-data-from-phase-3-pl9643-melody-1-clinical-trial-in-dry-eye-disease-at-arvo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-presents-breakthrough-symptom-resolution-data-from-phase-3-pl9643-melody-1-clinical-trial-in-dry-eye-disease-at-arvo-2025</guid>
<pubDate>Thu, 08 May 2025 20:30:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today presented new data from the Phase 3 MELODY-1 study at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The updated responder analyses highlight PL9643's rapid onset of action, broad and statistically significant efficacy, and complete symptom resolution across multiple endpoints in patients with dry eye dise</description>
</item>
<item>
<title>Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-technologies-announces-transition-to-otc-pink-following-nyse-american-delisting-notice</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-technologies-announces-transition-to-otc-pink-following-nyse-american-delisting-notice</guid>
<pubDate>Thu, 08 May 2025 00:26:00 GMT</pubDate>
<description>Palatin Technologies, Inc. ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system, today announced that it has received a notice from the NYSE American LLC ("NYSE American") stating that the NYSE Regulation has determined to commence proceedings to delist Palatin's common stock. The notice, issued under Section 1003(f)(v) of the NYSE American Company Guide, cites the low selling price of Palatin's common stock as t</description>
</item>
<item>
<title>Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-expects-dollar115-million-financing-to-cure-nyse-american-delisting-notice</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-expects-dollar115-million-financing-to-cure-nyse-american-delisting-notice</guid>
<pubDate>Wed, 07 May 2025 12:15:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (the "Company" or "Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that it expects to close its previously announced pricing of a public offering consisting of $11.5 million upfront and up to an additional $11.5 million upon the cash exercise of the milestone related warrants, on May 8, 2025. The Company believes the upfront</description>
</item>
<item>
<title>Palatin Technologies Announces Pricing of up to $23 Million Public Offering</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-technologies-announces-pricing-of-up-to-dollar23-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-technologies-announces-pricing-of-up-to-dollar23-million-public-offering</guid>
<pubDate>Wed, 07 May 2025 12:00:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its public offering with participation from new and existing healthcare focused institutional investors along with the Company's Chief Executive Officer, Chief Financial Officer, and certain board members, including the Chair consisting of 76,6</description>
</item>
<item>
<title>Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-presents-promising-preclinical-data-for-melanocortin-agonist-pl9588-at-arvo-2025-highlighting-a-dual-action-glaucoma-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-presents-promising-preclinical-data-for-melanocortin-agonist-pl9588-at-arvo-2025-highlighting-a-dual-action-glaucoma-therapy</guid>
<pubDate>Mon, 05 May 2025 11:30:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new preclinical data for PL9588, a novel melanocortin receptor agonist, presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The findings support the potential of PL9588 as a topical treatment for glaucoma, combining both IOP-lowering and neuroprotective effects.</description>
</item>
<item>
<title>Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease</title>
<link>https://6ix.com/company/palatin-technologies-inc/news/palatin-announces-breakthrough-symptom-resolution-in-updated-analyses-from-phase-3-pl9643-melody-1-clinical-trial-in-dry-eye-disease</link>
<guid isPermaLink="true">https://6ix.com/company/palatin-technologies-inc/news/palatin-announces-breakthrough-symptom-resolution-in-updated-analyses-from-phase-3-pl9643-melody-1-clinical-trial-in-dry-eye-disease</guid>
<pubDate>Tue, 29 Apr 2025 11:30:00 GMT</pubDate>
<description>Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced updated results from responder analyses of its pivotal Phase 3 MELODY-1 clinical trial evaluating the safety and efficacy of PL9643 versus placebo in the treatment of dry eye disease (DED).</description>
</item>
</channel>
</rss>